COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01161914
Recruitment Status : Withdrawn
First Posted : July 14, 2010
Last Update Posted : August 23, 2016
Information provided by:
ISU Abxis Co., Ltd.

Brief Summary:
The purpose of this study is to compare and evaluate the efficacy and safety of ISU302, an investigational product, and Cerezyme®, comparator, for Type 1 Gaucher Disease patients

Condition or disease Intervention/treatment Phase
Gaucher Disease Drug: Cerezyme® Drug: ISU302 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: A Multi-national Randomized Double Blinded Phase III Study to Evaluate the Safety and Efficacy of ISU302(Imiglucerase for Injection) or Cerezyme in Patient With Type I Gaucher Disease
Study Start Date : January 2011
Estimated Primary Completion Date : August 2011

Arm Intervention/treatment
Active Comparator: Cerezyme®
60 U/kg infusion (every 2 weeks for 24 weeks)
Drug: Cerezyme®
administered by IV infusion for a dose of 60 U/kg

Experimental: ISU302
60 U/kg infusion (every 2 weeks for 24 weeks)
Drug: ISU302
administered by IV infusion for a dose of 60 U/kg

Primary Outcome Measures :
  1. change in splenic volume compared to baseline [ Time Frame: one year ]
    Primary endpoints to demonstrate non-inferiority of ISU302 against Cerezyme® for change in splenic volume compared to baseline.

Secondary Outcome Measures :
  1. change in organ parameters and biochemical value compared to baseline [ Time Frame: one year ]
    • Change in splenic volume compared to baseline for all subjects enrolled
    • Change in hemoglobin concentration
    • Change in platelet counts
    • Change in liver volume compared to baseline
    • Change in range variation of liver function test (ALT/AST)
    • Change in skeletal status improvement level
    • Change in bone mineral density
    • Change in biomarkers (acid phosphatase, angiotensin-converting enzyme (ACE) and chitotriosidase)
    • After the 1st administration, to evaluate pharmacokinetic profile by glucocerebrosidase activity assay

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subjects have a diagnosis of Type I Gaucher Disease
  • Subjects between 2 years old and 75 years old
  • Subjects documented with glucocerebrosidase deficiency
  • Subjects with splenomegaly (as indicated by CT volumetric analysis as 5 times over than the standard size (0.2% of total body weight in kilograms))
  • A hemoglobin concentration level:Male > 12 years of age <12.0 g/dL Female>12 years of age<11.0 g/dL Child > 2 years of age and <12 years of age <10.5 g/dL
  • Platelet count of < 120,000 / ㎣
  • Treatment-naive to enzyme replacement therapy (ERT) or treatment- experienced subjects who have not received ERT in the 12 months before screening and antibody test result is negative
  • Treatment naive to substrate reduction therapy (SRT) or treatment- experienced subjects who have not received SRT in the 12 months before screening
  • Subjects or their spouses who provide consent to use one of following contraception methods, or women in menopause. (In this case, menopause is defined as a period after 12 months from the last menstruation)
  • Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (Spouse or patient who had vasectomy or tubal ligation/ hysterectomy)
  • Total abstinence from sexual intercourse: Female patient using oral contraceptives must use other contraception method (barrier method) also during the trial period and after the completion of trial as well as up to 90 days from the conclusion of trial.
  • The subject or their legal representative has signed the informed consent.

Exclusion Criteria:

  • Treatment with any investigational product in 90 days before study entry
  • Partial or total splenectomy
  • Subjects who have a serious concurrent disease like infection or who abuse addictive drug and substances.
  • Pregnant and/or breast-feeding women
  • Presence of Hepatitis B surface antigen or Hepatitis C or the patients show positive reaction to human immunodeficiency virus (HIV) type1
  • Subjects with a history of allergic reaction to Imiglucerase
  • Subjects with a history of severe pulmonary hypertension caused by Gaucher Disease
  • Any subject whom the investigator or the sub investigator considers as inad equate for this trial
Layout table for additonal information
Responsible Party: Lee, JaeHeung, ISU ABXIS CO., LTD Identifier: NCT01161914    
Other Study ID Numbers: ISU302-2008
First Posted: July 14, 2010    Key Record Dates
Last Update Posted: August 23, 2016
Last Verified: July 2010
Keywords provided by ISU Abxis Co., Ltd.:
Type I Gaucher
Additional relevant MeSH terms:
Layout table for MeSH terms
Gaucher Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders